Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies

Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies

An open-label dose escalation study of T-cell vaccination in multiple sclerosis patients was conducted using attenuated myelin reactive T-cells (MRTC) selected with six myelin peptides, two each from MBP, PLP and MOG. The dose range of subcutaneous injections given at weeks 0, 4, 12 and 20 was 6-9E6...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 131(2009), 2 vom: 15. Mai, Seite 202-15
1. Verfasser: Loftus, B (VerfasserIn)
Weitere Verfasser: Newsom, B, Montgomery, M, Von Gynz-Rekowski, K, Riser, M, Inman, S, Garces, P, Rill, D, Zhang, J, Williams, J C
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2009
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial Journal Article Immunologic Factors Myelin Basic Protein Vaccines Vaccines, Attenuated Vaccines, Subunit tovaxin
Online verfügbar Volltext